Form 10-Q Cell Source, Inc For: Sep 30 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ On July 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of Cell Source, Inc. (the "Company"). Neither Mr..
Darlene Soave Joins Cell Source s Board of Directors
News provided by
Share this article
Share this article
NEW YORK, April 1, 2021 /PRNewswire/ Cell Source, Inc. (OTC: CLCS) ( Cell Source or the Company ), is the world leader in Veto Cell based innovative immunotherapy and today announced that Darlene Soave has been appointed to the Company s Board of Directors, effective March 25, 2021. Veto Cells, in different mouse models, have shown that they have the potential to safely facilitate mismatched donor stem cell (e.g. bone marrow) transplants and organ transplants. In addition, in preclinical trials, Veto Cells have shown that they can durably treat malignant and non-malignant blood diseases through active immune response management.
USPTO Issues New Patents for Cell Source s Veto Cell Technology prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the Company"), the world leader in Veto Cell based immunotherapy technologies that can safely.